Table 1.

Survival analysis for the effect of nirmatrelvir and sotrovimab on the risk of negative PCR conversion (adjusted for age class, immunosuppression status, Omicron sub-lineage, time between the onset of symptoms and initiation of treatment, and cycle threshold value of nasopharyngeal PCR on day 0)

Variable		Hazard ratio	95% CI	p
Treatment	Nirmatrelvir vs. sotrovimab	2.35	1.56–3.56	<0.0001
Age (y)	≥80 vs. <80	0.71	0.45–1.15	0.17
Immunosuppressive conditions	Yes vs. no	0.63	0.43–0.91	0.01
Omicron sub-lineage	BA.2 vs. BA.1	1.51	1.12–2.01	0.01
Time between symptoms and initiation of treatment		0.99	0.88–1.08	0.90
Ct value of nasopharyngeal PCR on d 0		1.05	1.01–1.08	0.01

Ct, cycle threshold.